Ayse Bilge Ozturk1, Benjamin Arthur Turturice2, David L Perkins3,4,5, Patricia W Finn6,7. 1. Department of Allergy and Immunology, Koc University Hospital, Istanbul, Turkey. 2. Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA. 3. Department of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA. 4. Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA. 5. Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, USA. 6. Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL, USA. pwfinn@uic.edu. 7. Department of Medicine, University of Illinois at Chicago, Chicago, IL, 60612, USA. pwfinn@uic.edu.
Abstract
PURPOSE OF REVIEW: In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics. RECENT FINDINGS: Recent clinical and basic studies to date have identified several possible therapeutics that can target innate immunity and the microbiota in asthma. Some of these drugs have shown beneficial effects in the treatment of certain asthma phenotypes and for protection against asthma during early life. Current clinical evidence does not support the use of these therapies for effective treatment of asthma. The integration of the data regarding microbiota with technologic advances, such as next generation sequencing and omics offers promise. Combining comprehensive bioinformatics, new molecules and approaches may shape future asthma treatment.
PURPOSE OF REVIEW: In terms of immune regulating functions, analysis of the microbiome has led the development of therapeutic strategies that may be applicable to asthma management. This review summarizes the current literature on the gut and lung microbiota in asthma pathogenesis with a focus on the roles of innate molecules and new microbiome-mediated therapeutics. RECENT FINDINGS: Recent clinical and basic studies to date have identified several possible therapeutics that can target innate immunity and the microbiota in asthma. Some of these drugs have shown beneficial effects in the treatment of certain asthma phenotypes and for protection against asthma during early life. Current clinical evidence does not support the use of these therapies for effective treatment of asthma. The integration of the data regarding microbiota with technologic advances, such as next generation sequencing and omics offers promise. Combining comprehensive bioinformatics, new molecules and approaches may shape future asthma treatment.
Authors: Christian Rosas-Salazar; Meghan H Shilts; Andrey Tovchigrechko; James D Chappell; Emma K Larkin; Karen E Nelson; Martin L Moore; Larry J Anderson; Suman R Das; Tina V Hartert Journal: Am J Respir Crit Care Med Date: 2016-05-15 Impact factor: 21.405
Authors: J Riedler; C Braun-Fahrländer; W Eder; M Schreuer; M Waser; S Maisch; D Carr; R Schierl; D Nowak; E von Mutius Journal: Lancet Date: 2001-10-06 Impact factor: 79.321
Authors: Gary D Wu; Jun Chen; Christian Hoffmann; Kyle Bittinger; Ying-Yu Chen; Sue A Keilbaugh; Meenakshi Bewtra; Dan Knights; William A Walters; Rob Knight; Rohini Sinha; Erin Gilroy; Kernika Gupta; Robert Baldassano; Lisa Nessel; Hongzhe Li; Frederic D Bushman; James D Lewis Journal: Science Date: 2011-09-01 Impact factor: 47.728
Authors: Mariel Slater; Damian W Rivett; Lisa Williams; Matthew Martin; Tim Harrison; Ian Sayers; Kenneth D Bruce; Dominick Shaw Journal: Thorax Date: 2013-11-28 Impact factor: 9.139
Authors: Brittney M Donovan; Lisa Bastarache; Kedir N Turi; Mary M Zutter; Tina V Hartert Journal: Ann Allergy Asthma Immunol Date: 2019-09-05 Impact factor: 6.347